Read the Beforeitsnews.com story here. Advertise at Before It's News here.
Profile image
By Streetwise-The Energy Report (Reporter)
Contributor profile | More stories
Story Views
Now:
Last hour:
Last 24 hours:
Total:

Auctus Advisors Maintains Target Price on Oil Exploration Co. Following Production Update

% of readers think this story is Fact. Add your two cents.


Source: Stephane Foucaud 11/13/2024

The Auctus Advisors report highlighted Arrow Exploration Corp.’s (AXL:TSX.V; AXL:LSE) strong financial position.

Auctus Advisors analyst Stephane Foucaud, in a research report published on November 11, 2024, maintained a target price of £0.70 on Arrow Exploration Corp. (AXL:TSX.V; AXL:LSE). The report follows Arrow’s operational update on its Carrizales Norte wells and water disposal infrastructure.

Foucaud highlighted strong production from the company’s latest well, stating, “The fifth horizontal well at Carrizales Norte (CNB HZ-6) is producing 1.9 mbbl/d of oil (0.95 mbbl/d net to Arrow) with a water cut of 31%. The well reached TD ~ one month ago.”

The analyst noted consistent production across existing wells, commenting, “Overall current gross oil production from the existing horizontal wells (CNB HZ-1, HZ-3, HZ-4, and HZ-5 but excluding HZ-6) is 4.36 mbbl/d (2.18 mbbl/d net to Arrow) with each well producing 1-1.16 mbbl/d (gross).”

Regarding water management, Foucaud stated, “Arrow has now completed the water disposal facility at the CNB pad. The facility began operating on 2 November. Combined with the water disposal facilities at the CN and RCE pads, Arrow believes it has the ability to dispose of all water to be produced from those pads and increase the speed of the well pumps, adding initially 600-800 bbl/d of oil production (300-400 bbl/d net to Arrow).”

The report highlighted Arrow’s strong financial position, noting, “Arrow held US$18mm in cash on 11 November 2024, up US$3 mm compared to the cash position on 23 September. While the company has a very active drilling program, the cash increase over the last 6 weeks represents an annual cash build-up run rate of US$24 mm per year.”

Auctus Advisors’ valuation methodology is based on Net Asset Value (NAV). Foucaud explained, “Our Core NAV based on the company’s 2P reserves is £0.32/sh. Booking 4.35 mmbbl net reserves at Carrizales Noroeste in the next reserve report could add a further £0.25/sh to our Core NAV. Our ReNAV is £0.67/sh.”

In conclusion, Auctus Advisors’ maintenance of their £0.70 target price reflects confidence in Arrow Exploration’s operational execution and growth potential. The share price at the time of the report of £0.25 represents a potential return of approximately 180% to the analyst’s target price.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

  1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

Disclosures for Auctus Advisors, Arrow Exploration Corp., November 11, 2024

Arrow Exploration Corp.(“Arrow” or the “Company”) is a corporate client of Auctus Advisors LLP (“Auctus”).Auctus receives, and has received in the past 12 months, compensation for providing corporate broking and/or investmentbanking services to the Company, including the publication and dissemination of marketing material from time to time.MiFID II DisclosuresThis document, being paid for by a corporate issuer, is believed by Auctus to be an ‘acceptable minor non-monetary benefit’as set out in Article 12 (3) of the Commission Delegated Act C(2016)2031 which is part of UK law by virtue of the EuropeanUnion (Withdrawal) Act 2018.It is produced solely in support of our corporate broking and corporate finance business. Auctusdoes not offer a secondary execution service in the UK.This note is a marketing communication and NOT independent research. As such, it has not been prepared in accordancewith legal requirements designed to promote the independence of investment research and this note is NOT subject tothe prohibition on dealing ahead of the dissemination of investment research.AuthorThe research analyst who prepared this research report was Stephane Foucaud, a partner of Auctus.Not an offer to buy or sellUnder no circumstances is this note to be construed to be an offer to buy or sell or deal in any security and/or derivativeinstruments. It is not an initiation or an inducement to engage in investment activity under section 21 of the Financial Servicesand Markets Act 2000.Note prepared in good faith and in reliance on publicly available informationComments made in this note have been arrived at in good faith and are based, at least in part, on current public informationthat Auctus considers reliable, but which it does not represent to be accurate or complete, and it should not be relied on assuch.The information, opinions, forecasts and estimates contained in this document are current as of the date of thisdocument and are subject to change without prior notification. No representation or warranty either actual or implied is madeas to the accuracy, precision, completeness or correctness of the statements, opinions and judgements contained in thisdocument.Auctus’ and related interestsThe persons who produced this note may be partners, employees and/or associates of Auctus. Auctus and/or its employeesand/or partners and associates may or may not hold shares, warrants, options, other derivative instruments or other financialinterests in the Company and reserve the right to acquire, hold or dispose of such positions in the future and without priornotification to the Company or any other person.Information purposes onlyThis document is intended to be for background information purposes only and should be treated as such. This note is furnishedon the basis and understanding that Auctus is under no responsibility or liability whatsoever in respect thereof, whether totheCompany or any other person.Investment Risk WarningThe value of any potential investment made in relation to companies mentioned in this document may rise or fall and sumsrealised may be less than those originally invested. Any reference to past performance should not be construed as being aguide to future performance. Investment in small companies, and especially upstream oil & gas companies, carries a highdegree of risk and investment in the companies or commodities mentioned in this document may be affected by relatedcurrency variations. Changes inthe pricing of related currencies and or commodities mentioned in this document may havean adverse effect on the value, price or income of the investment.

DistributionThis document is directed at persons having professional experience in matters relating to investments to whom Article 19 ofthe Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (“FPO”) applies, or high net worth organisationsto whom Article 49 of the FPO applies. The investment or investment activity to which this communication relates is availableonly to such persons and other persons to whom this communication may lawfully be made (“relevant persons”) and will beengaged in only with such persons. This Document must not be acted upon or relied upon by persons who are not relevantpersons. Without limiting the foregoing, this note may not be distributed to any persons (or groups of persons), to whom suchdistributionwould contravene the UK Financial Services and Markets Act 2000 or would constitute a contravention of thecorresponding statute or statutory instrument in any other jurisdiction.DisclaimerThis note has been forwarded to you solely for information purposes only and should not be considered as an offer or solicitationof an offer to sell, buy or subscribe to any securities or any derivative instrument or any other rights pertaining thereto(“financial instruments”). This note is intended for use by professional and business investors only. This note may not bereproduced without the prior written consent of Auctus.The information and opinions expressed in this note have been compiled from sources believed to be reliable but, neitherAuctus, nor any of its partners, officers, or employees accept liability from any loss arising from the use hereof or makes anyrepresentations as to its accuracy and completeness. Any opinions, forecasts or estimates herein constitute a judgement as atthe date of this note. There can be no assurance that future results or events will be consistent with any such opinions,forecasts or estimates. Past performance should not be taken as an indication or guarantee of future performance, and norepresentation or warranty, express or implied is made regarding future performance. This information is subject to changewithout notice, its accuracy is not guaranteed, it may be incomplete or condensed and it may not contain all materialinformation concerning the company and its subsidiaries. Auctus is not agreeing to nor is it required to update the opinions,forecasts or estimates contained herein.The value of any securities or financial instruments mentioned in this note can fall as well as rise. Foreign currencydenominated securities and financial instruments are subject to fluctuations in exchange rates that may have a positive oradverse effecton the value, price or income of such securities or financial instruments. Certain transactions, including thoseinvolving futures, options and other derivative instruments, can give rise to substantial risk and are not suitable for allinvestors. This note does not have regard to the specific instrument objectives, financial situation and the particular needs ofany specific person who may receive this note.Auctus (or its partners, officers or employees) may, to the extent permitted by law, own or have a position in the securitiesor financial instruments (including derivative instruments or any other rights pertaining thereto) of the Company or any relatedor other company referred to herein, and may add to or dispose of any such position or may make a market or act as principle in any transaction in such securities or financial instruments. Partners of Auctus may also be directors of the Company or anyother of the companies mentioned in this note. Auctus may, from time to time, provide or solicit investment banking or otherfinancial services to, for or from the Company or any other companyreferred to herein. Auctus (or its partners, officers oremployees) may, to the extent permitted by law, act upon or use the information or opinions presented herein, or researchor analysis on which they are based prior to the material being published.Further Disclosures for the United KingdomThis note has been issued by Auctus Advisors LLP, which is authorised and regulated by the Financial Conduct Authority.Thisnote is not intended for use by, or distribution to, US corporations that do not meet the definition of a major US institutionalinvestor in theUnited States or for use by any citizen or resident of the United States.This publication is confidential and may not be reproduced in whole or in part or disclosed to another party, without the priorwritten consent of Auctus. Securities referred to in this note may not be eligible for sale in those jurisdictions where Auctusis not authorised or permitted by local law to do so. In particular, Auctus does not permit the distribution or redistribution ofthis note to non-professional investors or other persons to whom disclosure would contravene local securities laws. Auctusexpressly disclaims and will not be held responsible in any way, for third parties who affect such redistribution.© Auctus Advisors LLP All rights reserved 2024.

( Companies Mentioned: AXL:TSX.V; AXL:LSE, )


Source: https://www.streetwisereports.com/article/2024/11/13/auctus-advisors-maintains-target-price-on-oil-exploration-co-following-production-update.html


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.


LION'S MANE PRODUCT


Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules


Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.



Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.


Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

MOST RECENT
Load more ...

SignUp

Login

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.